http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3832376
We need to increase and improve investments in health, especially for strengthening the first level of care, and to… twitter.com/i/web/status/9…
We need to increase and improve investments in health, especially for strengthening the first level of care, and to… twitter.com/i/web/status/9…
We need to increase and improve investments in health, especially for strengthening the first level of care, and to… twitter.com/i/web/status/9…
It has been estimated that if timely, accessible, high quality health services had existed in the Americas in 2013-… twitter.com/i/web/status/9…
It has been estimated that if timely, accessible, high quality health services had existed in the Americas in 2013-… twitter.com/i/web/status/9…
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831732
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831250
http://portal.anvisa.gov.br/web/guest/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/3831053
The draft document of ‘WHO Questions and Answers: Similar Biotherapeutic Products’ is available at WHO biological website (http://www.who.int/biologicals/en/). WHO is requesting a feedback from a broad audience of regulators, manufacturers, and other experts. The document is going to be exposed to the public by 23 Feb 2018.
You could download the document directly by clicking on the following link:
http://www.who.int/biologicals/QA_for_SBPs_HK_12_Dec_2017_(2).pdf?ua=1.
In order to provide your comments, please use the template, http://www.who.int/entity/biologicals/WHO_QA_Comment_Form_WHO_QA_30_Nov_2017.doc?ua=1.
If you prefer, you could also use the draft document and comment form attached in this email.
In case that you need any other information, please contact Dr HyeNa KANG (Scientist, Technologies Standards and Norms (Team),Essential Medicines and Health Products (Department), WHO) by kangh@who.int.
